Hepatitis D - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Hepatitis D - Pipeline Review, H1 2016', provides an overview of the Hepatitis D pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hepatitis D, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hepatitis D and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Hepatitis D - The report reviews pipeline therapeutics for Hepatitis D by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Hepatitis D therapeutics and enlists all their major and minor projects - The report assesses Hepatitis D therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Hepatitis D Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Hepatitis D - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Hepatitis D pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Content 2 List of Tables 5 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Hepatitis D Overview 7 Therapeutics Development 8 Pipeline Products for Hepatitis D - Overview 8 Pipeline Products for Hepatitis D - Comparative Analysis 9 Hepatitis D - Therapeutics under Development by Companies 10 Hepatitis D - Therapeutics under Investigation by Universities/Institutes 11 Hepatitis D - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Hepatitis D - Products under Development by Companies 14 Hepatitis D - Products under Investigation by Universities/Institutes 15 Hepatitis D - Companies Involved in Therapeutics Development 16 Alnylam Pharmaceuticals, Inc. 16 BioDiem Ltd 17 Eiger BioPharmaceuticals, Inc. 18 Globeimmune, Inc. 19 REPLICor Inc. 20 SomaGenics, Inc. 21 Spring Bank Pharmaceuticals, Inc. 22 Hepatitis D - Therapeutics Assessment 23 Assessment by Monotherapy Products 23 Assessment by Target 24 Assessment by Mechanism of Action 26 Assessment by Route of Administration 28 Assessment by Molecule Type 30 Drug Profiles 32 ALN-HDV - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 GI-18000 - Drug Profile 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 hepatitis D vaccine - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 lonafarnib - Drug Profile 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 Myrcludex-B - Drug Profile 37 Product Description 37 Mechanism of Action 37 R&D Progress 37 REP-2139 - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 REP-2165 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 RNAi Oligonucleotide for Hepatitis D - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 SB-9200 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 vanitaracin A - Drug Profile 45 Product Description 45 Mechanism of Action 45 R&D Progress 45 Hepatitis D - Recent Pipeline Updates 46 Hepatitis D - Dormant Projects 54 Hepatitis D - Product Development Milestones 55 Featured News & Press Releases 55 Apr 04, 2016: Replicor to Make Three Presentations at EASL 2016 55 Mar 30, 2016: Eiger BioPharmaceuticals Announces Abstracts and Presentations of Lonafarnib Data in Hepatitis Delta at the European Association for the Study of the Liver Meeting 55 Mar 23, 2016: Maxwell Biotech Venture Fund's Portfolio Company Hepatera Announces Start of Phase 2b clinical trial of Myrcludex B, a Novel Entry Inhibitor for Treatment of Chronic HBV and HDV Infection 56 Mar 14, 2016: Eiger BioPharmaceuticals Announces Completion of Enrollment of Phase 2 LOWR HDV - 4 (LOnafarnib With Ritonavir in Hepatitis Delta Virus - 4) Study at Hannover Medical School 56 Jan 19, 2016: Eiger BioPharmaceuticals Announces Completion of Enrollment of Phase 2 LOWR HDV - 3 (LOnafarnib With Ritonavir in Hepatitis Delta Virus - 3) Study at National Institutes of Health 57 Jan 06, 2016: Eiger BioPharmaceuticals Announces First Patient Dosed in Phase 2 LOWR HDV - 4 (LOnafarnib With Ritonavir in Hepatitis Delta Virus - 4) Study at Hannover Medical School in Hannover, Germany 57 Jul 20, 2015: The Lancet Infectious Diseases Journal Publishes Results of Phase 2 Study of Lonafarnib in Hepatitis Delta Virus Infected Patients 58 Jun 30, 2015: Replicor Discloses Updated Clinical Trial Data to the Global Virus Hepatitis Summit in Berlin 58 Jun 10, 2015: Replicor to Present at the Israel Association for the Study of Liver Conference and the Global Virus Hepatitis Summit in Berlin in June 59 Apr 29, 2015: Significant Reduction of HBsAg and HDV RNA by REP 2139-Ca in Caucasian Patients with HBV / HDV Co-Infection 59 Appendix 60 Methodology 60 Coverage 60 Secondary Research 60 Primary Research 60 Expert Panel Validation 60 Contact Us 60 Disclaimer 61
List of Tables
Number of Products under Development for Hepatitis D, H1 2016 8 Number of Products under Development for Hepatitis D - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Number of Products under Investigation by Universities/Institutes, H1 2016 11 Comparative Analysis by Clinical Stage Development, H1 2016 12 Comparative Analysis by Early Stage Development, H1 2016 13 Products under Development by Companies, H1 2016 14 Products under Investigation by Universities/Institutes, H1 2016 15 Hepatitis D - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016 16 Hepatitis D - Pipeline by BioDiem Ltd, H1 2016 17 Hepatitis D - Pipeline by Eiger BioPharmaceuticals, Inc., H1 2016 18 Hepatitis D - Pipeline by Globeimmune, Inc., H1 2016 19 Hepatitis D - Pipeline by REPLICor Inc., H1 2016 20 Hepatitis D - Pipeline by SomaGenics, Inc., H1 2016 21 Hepatitis D - Pipeline by Spring Bank Pharmaceuticals, Inc., H1 2016 22 Assessment by Monotherapy Products, H1 2016 23 Number of Products by Stage and Target, H1 2016 25 Number of Products by Stage and Mechanism of Action, H1 2016 27 Number of Products by Stage and Route of Administration, H1 2016 29 Number of Products by Stage and Molecule Type, H1 2016 31 Hepatitis D Therapeutics - Recent Pipeline Updates, H1 2016 46 Hepatitis D - Dormant Projects, H1 2016 54
List of Figures
Number of Products under Development for Hepatitis D, H1 2016 8 Number of Products under Development for Hepatitis D - Comparative Analysis, H1 2016 9 Number of Products under Development by Companies, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 13 Assessment by Monotherapy Products, H1 2016 23 Number of Products by Targets, H1 2016 24 Number of Products by Stage and Targets, H1 2016 24 Number of Products by Mechanism of Actions, H1 2016 26 Number of Products by Stage and Mechanism of Actions, H1 2016 26 Number of Products by Routes of Administration, H1 2016 28 Number of Products by Stage and Routes of Administration, H1 2016 28 Number of Products by Molecule Types, H1 2016 30 Number of Products by Stage and Molecule Types, H1 2016 30
Global Automated Test Equipment (ATE) market is expected to be valued at USD 4.48 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing design complexity coupled with need for effective testing is expected to drive the glRead More...
Global alpha olefins market size is likely to be valued at USD 10.7 billion by 2020; as per a new research report by Radiant Insights, Inc. Increasing polyethylene demand for use in plastic production is anticipated to drive market growth. Growing apRead More...
Global animal feed additives market size was estimated at USD 16 billion in 2014. Growing meat consumption as a key protein source, especially in Asia Pacific and Latin America is expected to be a key driver for market demand over the forecast periodRead More...
Global commercial drone market size is estimated to reach USD 2,069.6 million by 2022, as per a new research report by Radiant Insights, Inc. Increasing application of these machines in various industry sectors such as military, agriculture and energRead More...
Global 3D scanning market is expected to be valued at USD 4,900.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing need for speedy and precise results with high efficiency is anticipated to drive the industry. 3DRead More...
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.